A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Feb 1, 2013

Astellas Announces Relocation of Global HQ building in Tokyo

Read more about Astellas Announces Relocation of Global HQ building in Tokyo
Feb 1, 2013

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Jan 30, 2013

Enzalutamide Data to Be Presented at ASCO GU Symposium

Read more about Enzalutamide Data to Be Presented at ASCO GU Symposium
Jan 29, 2013

AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 ASCO Genitourinary Cancers Symposium

Read more about AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 ASCO Genitourinary Cancers Symposium
Jan 16, 2013

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR TARCEVA® (ERLOTINIB) TABLETS FOR GENETICALLY DISTINCT FORM OF ADVANCED LUNG CANCER

– The Tarceva application has been granted priority review –

Read more about FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR TARCEVA® (ERLOTINIB) TABLETS FOR GENETICALLY DISTINCT FORM OF ADVANCED LUNG CANCER
Jan 11, 2013

NEW CLASS OF TREATMENT FOR OVERACTIVE BLADDER APPROVED IN EUROPE

Astellas Pharma Europe Ltd., Chertsey, UK, 11th January 2013. A new treatment, BETMIGATM (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive...

Read more about NEW CLASS OF TREATMENT FOR OVERACTIVE BLADDER APPROVED IN EUROPE
Jan 10, 2013

Astellas and Sanwa Launch “ARGAMATE® 89.29% Granule 5.6g” - Hyperkalemia Treatment

Read more about Astellas and Sanwa Launch “ARGAMATE® 89.29% Granule 5.6g” - Hyperkalemia Treatment
Dec 25, 2012

Astellas and UCB announce approval of Cimzia®(certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis

Tokyo, Japan and Brussels, Belgium, 25th December, 2012 – Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and UCB S.A. (“UCB"; Brussels, Belgium, CEO:...

Read more about Astellas and UCB announce approval of Cimzia®(certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis
Dec 21, 2012

Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug

- The first combination drug of a high-dose ARB and a long acting CCB with a powerful antihypertensive effect lasting for 24 hours in Japan -

Tokyo, Japan, December 21, 2012 – Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo; President: Yoshiaki Aono; hereinafter “NBI”) and Astellas Pharma Inc. (Tokyo:4503,...

Read more about Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug
Dec 14, 2012

Astellas announces recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections

Read more about Astellas announces recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts